Reprogramming.
Hematopoiesis.
Immunity.
Lab
We are studying how hematopoietic cell fate is specified, maintained, and eventually modified or reversed. Inspired from the fields of stem cell biology, immunology, and cancer we use an interdisciplinary approach to mechanistically understand hematopoietic and immune cell identities and translate our findings into novel gene and cell therapies.
Research
Merging Stem Cells with Immunology by Cell Fate Reprogramming. Learn more about our research lines:
Latest Publications
In Vivo Dendritic Cell Reprogramming for Cancer Immunotherapy
Ervin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannova, Xavier Catena, Nadezhda Rotankova, Charlotte Veser, Michal Rudnik, Tommaso Ballocci, Tiffany Schärer, Xiaoli Huang, Maria de Rosa Torres, Emilie Renaud, Marta Velasco Santiago, Özcan Met, David Askmyr, Malin Lindstedt, Lennart Greiff, Laure-Anne Ligeon, Irina Agarkova, Inge Marie Svane, Cristiana F. Pires, Fábio F. Rosa, and Carlos-Filipe Pereira
September 5, 2024
Science
GATA2 Mitotic Bookmarking Is Required for Definitive Haematopoiesis
Rita Silvério-Alves, Ilia Kurochkin, Anna Rydström, Camila Vazquez Echegaray, Jakob Haider, Matthew Nicholls, Christina Rode, Louise Thelaus, Aida Yifter Lindgren, Alexandra Gabriela Ferreira, Rafael Brandão, Jonas Larsson, Marella de Bruijn, Javier Martin-Gonzalez, Carlos-Filipe Pereira
August 14, 2023 / 14:4645
Nature Communications
Team
We are a diverse group – molecular biologists, MDs, PharmDs, tumor immunologists, stem cell biologists and computational scientists – at all career stages. We architect strategies to dissect and manipulate immune cell identity.
Looking for an opportunity? Join our international team!
Funders
Latest News
In Vivo Dendritic Cell Reprogramming for Cancer Immunotherapy
The Pereira Lab reports for the first time the in vivo reprogramming of cancer cells into type 1 conventional dendritic cells (cDC1s). The study was published in Science and showcases a new cancer immunotherapy modality.
Beatriz Vaz and Mariana Gonçalves awarded with PhD Studentships from The Foundation for Science and Technology (FCT)
The researchers Beatriz Vaz and Mariana Gonçalves from Pereira Lab were awarded with PhD studentships from the Foundation for Science and Technology (FCT). Both PhD projects aim to surpass the limitations of current cancer immunotherapies, addressing different strategies to reprogram cancer cells into antigen-presenting type 1 conventional dendritic cells (cDC1s), which are pivotal for anti-tumor immunity.
The European Research Council (ERC) awards the project DART with an ERC Proof of Concept
The Pereira Lab secures its third ERC grant with the project DART – “Driving Tumor Antigen Presentation by RNA-mediated Transdifferentiation.” The awarded project aims to develop an effective approach to perform RNA-based reprogramming of tumor cells into dendritic cells. DART is built on clinical and industry collaborations: Cristiana Pires and Fábio Rosa from Asgard Therapeutics, Anders Wittrup from Lund University, and Inge Marie Svane from Herlev Hospital in Denmark.